XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.26.1

FINANCIAL INSTRUMENTS (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Investments, Debt and Equity Securities [Abstract] |
Schedule of Cash, Cash Equivalents, Restricted Cash Equivalents and Available-for-Sale Securities by Significant Investment Category | The following tables show the Company’s cash, cash equivalents, restricted cash equivalents and available-for-sale securities by significant investment category as of the dates presented:
| March 31, 2026
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Aggregate Fair Value |  | Cash and Cash Equivalents |  | Restricted Cash Equivalents |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 352,248 |  |  | $ | — |  |  | $ | — |  |  | $ | 352,248 |  |  | $ | 352,248 |  |  | $ | — |  |  |  |  |
Level 2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market instruments | 2,720,187 |  |  | — |  |  | — |  |  | 2,720,187 |  |  | 1,870,187 |  |  | 850,000 |  |  |  |  |
Total | $ | 3,072,435 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,072,435 |  |  | $ | 2,222,435 |  |  | $ | 850,000 |  |  |  |  |
| December 31, 2025
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Aggregate Fair Value |  | Cash and Cash Equivalents |  | Short-term Marketable Securities (1) |  | Long-term Marketable Securities (2)
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 415,760 |  |  | $ | — |  |  | $ | — |  |  | $ | 415,760 |  |  | $ | 415,760 |  |  | $ | — |  |  | $ | — |
Level 2: |  |  |  |  |  |  |  |  |  |  |  |  |
Money market instruments | 895,919 |  |  | — |  |  | — |  |  | 895,919 |  |  | 895,919 |  |  | — |  |  | — |
Corporate debt securities | 472,572 |  |  | 3,286 |  |  | (3) |  |  | 475,855 |  |  | — |  |  | 189,566 |  |  | 286,289 |
U.S. government agency securities | 206,018 |  |  | 1,197 |  |  | (1) |  |  | 207,214 |  |  | — |  |  | 59,115 |  |  | 148,099 |
Asset-backed securities | 57,687 |  |  | 420 |  |  | (4) |  |  | 58,103 |  |  | — |  |  | 249 |  |  | 57,854 |
Subtotal | 1,632,196 |  |  | 4,903 |  |  | (8) |  |  | 1,637,091 |  |  | 895,919 |  |  | 248,930 |  |  | 492,242 |
Total | $ | 2,047,956 |  |  | $ | 4,903 |  |  | $ | (8) |  |  | $ | 2,052,851 |  |  | $ | 1,311,679 |  |  | $ | 248,930 |  |  | $ | 492,242 |
(1) The Company’s short-term marketable securities as of December 31, 2025 mature in one year or less, and were liquidated in the first quarter of 2026 to fund the Amicus Therapeutics, Inc. (Amicus) acquisition that closed in April 2026. (2) The Company’s long-term marketable securities as of December 31, 2025 mature between one and five years, and were liquidated in the first quarter of 2026 to fund the Amicus acquisition that closed in April 2026.
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported on the Company’s Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows:
| March 31, 2026 |  |
Cash and cash equivalents | $ | 2,222,435 |  |  |
Restricted cash equivalents | 850,000 |  |  |
Cash, cash equivalents and restricted cash equivalents | $ | 3,072,435 |  |  |
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported on the Company’s Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows:
| March 31, 2026 |  |
Cash and cash equivalents | $ | 2,222,435 |  |  |
Restricted cash equivalents | 850,000 |  |  |
Cash, cash equivalents and restricted cash equivalents | $ | 3,072,435 |  |  |

X
- Definition Schedule of cash, cash equivalents and available-for-sale securities. + References No definition available. + Details
Name: | bmrn_ScheduleOfCashCashEquivalentsRestrictedCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock
Namespace Prefix: | bmrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details
Name: | us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration